Business Wire

Mavenir and HCL Collaborate on Integration and Delivery of O-RAN Compliant Radios

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced a strategic partnership with HCL Technologies (HCL), a leading global technology company with expertise in network systems testing. This partnership helps accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) while establishing a business model to meet the growing demand and evolving requirements for O-RAN RRUs.

Today’s RRU ecosystem has expanded to offer Communication Service Providers (CSPs) a significantly wider choice of 2G, 3G, 4G, 5G, massive MIMO (mMIMO), millimeter Wave (mmWave), small cell and indoor radios. In turn, the number of RRU partners that Mavenir works with continues to grow, with each partner releasing new and sophisticated radios, with new software, across different radio technologies, output power, antenna dimensions and spectrum to meet the evolving needs of O-RAN customers.

The collaboration brings together HCL’s platform for third-party RRU testing and Mavenir’s full Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks. RRU vendors will, as a result, be given the ability to work directly with HCL to assess their O-RAN interfaces and integrate with Mavenir’s O-RAN compliant cloud-native CU/DU software.

By simplifying testing and validation across multiple O-RAN interoperability profiles, the collaboration will help vendors fast-track validation of frequency variants and the increasingly diverse RRU offerings being demanded by the O-RAN market.

This partnership will benefit both RRU vendors and CSPs by supporting the continued expansion of the radio ecosystem and helping to establish a self-sustaining RRU business model:

  • Vendors will be able to rapidly validate their O-RAN compliant RRUs as they develop portfolios of products targeted at different deployment scenarios.
  • CSPs will be able to more easily identify the available O-RAN compliant RRU options for specific use cases and locations.

“We are directly addressing requests from customers and partners to speed the integration of new RRU products. The growing scale of the O-RAN industry now demands such a model. And thanks to O-RAN and open interfaces, new players such as HCL can enter the market to effectively serve the market needs,” said Mavenir’s Puneet Sethi, SVP/GM RAN Business Unit. “As more O-RAN RRU products become available and RRU partners are enabled to respond rapidly to their customers, CSPs worldwide will be able to take advantage of the full range of their spectrum assets and benefit from the rapidly accelerating RRU ecosystem.”

“The Mavenir-HCL partnership helps accelerate the O-RAN market, bringing a new suite of product offerings to CSPs and enterprises alike. This sets the stage for a nascent ecosystem accelerating future innovation across key verticals on a global scale,” said HCL’s Rajiv Shesh, Corporate Vice President, Engineering and R&D Services. “HCL is bringing together many decades of network testing experience, 5G expertise, state of the art lab facilities and advanced automation tools to validate the interoperability between Mavenir and RRU partners. HCL provides the necessary visibility and reporting capability that enables operators and enterprises in deploying best-of-breed Mavenir O-RAN solutions.”

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maryvonne Tubb
Mavenir
PR@mavenir.com

Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com

Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bentley Education Program Expands to Global Scope25.10.2021 23:01:00 EEST | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, as a commitment to expand access to its professional applications to education, today announced the global expansion of the Bentley Education program – offering seamless access to learning licenses of over 60 popular Bentley applications, at no cost, to all eligible students and educators, from middle schools through higher education levels, via the Bentley Education portal. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005717/en/ The Bentley Education program helps students develop digital skills that are critical for a qualified talent pipeline to support infrastructure growth and resilience worldwide. (Photo: Business Wire) Following on the initial May 3, 2021 announcement of the launch of Bentley Education in the pilot countries of Australia, the UK, Singapore, Lithuania, and Ireland, the program is gaining a resounding r

X-Chem Acquires ComInnex25.10.2021 21:00:00 EEST | Press release

X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery. With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market. “As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark, Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help bio

European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-1925.10.2021 17:30:00 EEST | Press release

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.1,2 “We are gratified the European Commission has recognized the potential of lenzilumab to offer an important treatment option for patients hospitalized with COVID-19,” said Cameron Durrant, MD, Chairman and CEO, Humanigen. “We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19. We are also progressing with our early access program, under compassionate use, where allowed by regulations in some European countries and the United States.” *Lenzilumab is not authorized, or approved

Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 202125.10.2021 15:00:00 EEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis evaluated the safety and efficacy of investigational RBX2660 among a broad cohort of CDI patients with comorbidities commonly found in patients with CDI, and was recognized with a Presidential Poster Award for high-quality, novel, unique and interesting research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005099/en/ Ferring Fact Sheet While the eligibility criteria in prospective clinical trials often are narrowly defined to include patients diagnosed with only CDI, this analysis allowed researchers to evaluate the impact of RBX2660 in a patient population that is more reflective of a real-world setting. In the analysis, 94 participants with comorbid conditions commonly found in people with recurrent CDI (rCDI) were trea

Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma25.10.2021 15:00:00 EEST | Press release

EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/ Standard Color Vision and Color Blind View @EnChroma In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering

Rockefeller Capital Management to Open First International Office in London with the Formation of Rockefeller Asset Management International25.10.2021 15:00:00 EEST | Press release

Rockefeller Asset Management (RAM), a division of Rockefeller Capital Management, with a long track record of investing in global equities and ESG investing has announced the formation of Rockefeller Asset Management International, to expand its European market presence. The initial plans for expansion include opening an office in London, to better serve clients across the UK, Europe, and Asia. “Our Asset Management business has generated real momentum across Europe and we are excited to continue to serve our international clients with a full suite of sustainable investment products and a growing local presence,” said Greg Fleming, CEO and President of Rockefeller Capital Management. RAM, which was recently awarded the 2021 Principles for Responsible Investing (PRI) award for “ESG incorporation initiative of the year,” has seen strong growth in Europe. Over the last two years, the business, which surpassed $2.5 billion in assets from European investors, launched a UCITS ICAV, an Irelan

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention25.10.2021 14:53:00 EEST | Press release

Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden. CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom